Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,308
archived clinical trials in
Hepatitis

A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated:  11/2/2017
University of California, San Francisco - Hepatitis/HIV Clinical Trials Group (HHCTG)
mi
from
San Francisco, CA
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated: 11/2/2017
University of California, San Francisco - Hepatitis/HIV Clinical Trials Group (HHCTG)
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated:  11/2/2017
University of California, San Francisco - Mt. Zion Hospital
mi
from
San Francisco, CA
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated: 11/2/2017
University of California, San Francisco - Mt. Zion Hospital
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated:  11/2/2017
Georgia Regents Medical Center
mi
from
Augusta, GA
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated: 11/2/2017
Georgia Regents Medical Center
mi
from
Augusta, GA
Click here to add this to my saved trials
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated:  11/2/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated: 11/2/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated:  11/2/2017
Mount Sinai Faculty Practice Associates
mi
from
New York, NY
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated: 11/2/2017
Mount Sinai Faculty Practice Associates
mi
from
New York, NY
Click here to add this to my saved trials
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated:  11/2/2017
Mount Sinai Hosp
mi
from
New York, NY
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated: 11/2/2017
Mount Sinai Hosp
mi
from
New York, NY
Click here to add this to my saved trials
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated:  11/2/2017
Southwest Infectious Disease Clinical Research, Inc
mi
from
Dallas, TX
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated: 11/2/2017
Southwest Infectious Disease Clinical Research, Inc
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated:  11/2/2017
UT Southwestern Medical Center
mi
from
Dallas, TX
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated: 11/2/2017
UT Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated:  11/2/2017
Fakultni nemocnice Brno
mi
from
Brno,
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
A Multicenter, Randomized, Blinded, Placebo-controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In Hiv-1-infected Subjects Co-infected With Hepatitis C And/or Hepatitis B Virus
Status: Enrolling
Updated: 11/2/2017
Fakultni nemocnice Brno
mi
from
Brno,
Click here to add this to my saved trials
Risk Assessment of Long-Haul Truck Drivers
Risk Assessment of Long-Haul Truck Drivers
Status: Enrolling
Updated:  11/3/2017
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Risk Assessment of Long-Haul Truck Drivers
Risk Assessment of Long-Haul Truck Drivers
Status: Enrolling
Updated: 11/3/2017
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Evaluation of Serum Chemokines for Patients Undergoing Treatment With Boceprevir.
Evaluation of Serum Chemokines for Patients Undergoing Treatment With Boceprevir.
Status: Enrolling
Updated:  11/6/2017
University of North Carolina Liver Center
mi
from
Chapel Hill, NC
Evaluation of Serum Chemokines for Patients Undergoing Treatment With Boceprevir.
Evaluation of Serum Chemokines for Patients Undergoing Treatment With Boceprevir.
Status: Enrolling
Updated: 11/6/2017
University of North Carolina Liver Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Birmingham, AL
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Tucson, AZ
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Tucson, AZ
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
North Little Rock, AR
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
North Little Rock, AR
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Bakersfield, CA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
La Jolla, CA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
La Jolla, CA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Newport Beach, CA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Pasadena, CA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Pasadena, CA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Sacramento, CA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Sacramento, CA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
San Clemente, CA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
San Clemente, CA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
San Francisco, CA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Santa Clara, CA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Santa Clara, CA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Englewood, CO
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Englewood, CO
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Washington,
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Washington,
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Fort Lauderdale, FL
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Miami, FL
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Orlando, FL
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Sarasota, FL
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Sarasota, FL
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Atlanta, GA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Marietta, GA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Marietta, GA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Honolulu, HI
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Honolulu, HI
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Indianapolis, IN
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Iowa City, IA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Iowa City, IA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Louisville, KY
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Louisville, KY
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Boston, MA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Worcester, MA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Worcester, MA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Ann Arbor, MI
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Detroit, MI
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Detroit, MI
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Binghamton, NY
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Binghamton, NY
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Manhasset, NY
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Manhasset, NY
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
New York, NY
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Syracuse, NY
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Syracuse, NY
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Chapel Hill, NC
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Durham, NC
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Durham, NC
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Cincinnati, OH
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Cleveland, OH
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Tulsa, OK
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Tulsa, OK
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Hershey, PA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Hershey, PA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Lancaster, PA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Lancaster, PA
Click here to add this to my saved trials